CD89 Antibody (A3): sc-19680

CD89 Antibody (A3) is a mouse monoclonal IgG1 kappa light chain antibody that detects CD89 protein of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). CD89 (A3) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. CD89, also known as Immunoglobulin alpha Fc receptor (Fc α RI), plays a crucial role in the immune response by binding to aggregated IgA, which is essential for the clearance of pathogens and immune complexes. This glycoprotein is predominantly expressed on the surface of immune cells such as neutrophils, monocytes, macrophages, and eosinophils, where CD89 acts as a potent cytotoxic trigger. CD89 interaction with IgA not only facilitates the endocytosis of IgA-coated antigens but also enhances antibody production in B cells through T cell antigen presentation, thereby amplifying the immune response. Additionally, cytokines can induce a high-affinity binding state for CD89, which is mediated by CD89′s intracellular C-terminus, highlighting CD89′s dynamic role in immune regulation. Notably, polymorphisms in the gene encoding CD89 have been linked to an increased susceptibility to IgA nephropathy, a glomerulonephritis characterized by the deposition of IgA antibodies in the kidney glomeruli, underscoring CD89′s clinical significance in both health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CD89 Antibody (A3) References:

1. Polymorphism in promoter region of Fcalpha receptor gene in patients with IgA nephropathy.  |  Tsuge, T., et al. 2001. Hum Genet. 108: 128-33. PMID: 11281451
2. Insights into IgA-mediated immune responses from the crystal structures of human FcalphaRI and its complex with IgA1-Fc.  |  Herr, AB., et al. 2003. Nature. 423: 614-20. PMID: 12768205
3. The gene for the human IgA Fc receptor maps to 19q13.4.  |  Kremer, EJ., et al. 1992. Hum Genet. 89: 107-8. PMID: 1577457
4. Functionality of the IgA Fc receptor (FcalphaR, CD89) is down-regulated by extensive engagement of FcepsilonRI.  |  Matsui, T., et al. 2008. Clin Immunol. 129: 155-62. PMID: 18700185
5. Inside-out regulation of Fc alpha RI (CD89) depends on PP2A.  |  Bakema, JE., et al. 2008. J Immunol. 181: 4080-8. PMID: 18768864
6. Functional expression of IgA receptor FcalphaRI on human platelets.  |  Qian, K., et al. 2008. J Leukoc Biol. 84: 1492-500. PMID: 18784345
7. Analysis of IgA1 N-glycosylation and its contribution to FcalphaRI binding.  |  Gomes, MM., et al. 2008. Biochemistry. 47: 11285-99. PMID: 18826328
8. Soluble CD89 is a critical factor for mesangial proliferation in childhood IgA nephropathy.  |  Cambier, A., et al. 2022. Kidney Int. 101: 274-287. PMID: 34756952
9. Targeting CD89 on tumor-associated macrophages overcomes resistance to immune checkpoint blockade.  |  Xu, L., et al. 2022. J Immunother Cancer. 10: PMID: 36460336
10. Antagonizing FcαR1 (CD89) as treatment in IgA-mediated chronic inflammation and autoimmunity.  |  van Delft, MAM., et al. 2023. Front Immunol. 14: 1118539. PMID: 37081893
11. SIgA structures bound to Streptococcus pyogenes M4 and human CD89 provide insights into host-pathogen interactions.  |  Liu, Q. and Stadtmueller, BM. 2023. Nat Commun. 14: 6726. PMID: 37872175
12. Structure of the gene for the human myeloid IgA Fc receptor (CD89).  |  de Wit, TP., et al. 1995. J Immunol. 155: 1203-9. PMID: 7636188

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-CD89 Antibody (A3) has 2 citations in a variety of scientific publications.

Primary antibodies like Anti-CD89 Antibody (A3) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

CD89 Antibody (A3) Specifications

Alternate Product Name: CD89

Product Clone Name: A3

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids:

Epitope Target: CD89

Epitope Species: human

Product Reactivity/Detection: CD89

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, FCM

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 2 citations in various scientific publications

Available Conjugates/Forms for CD89 Antibody (A3): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin